Olle Sangfelt
Senior Forskare | Docent
E-postadress: olle.sangfelt@ki.se
Telefon: +46852486395
Besöksadress: Solnavägen 9, 17165 Stockholm
Postadress: C5 Cell- och molekylärbiologi, C5 CMB Sangfelt, 171 77 Stockholm
Del av:
- Institutionen för cell- och molekylärbiologi
- Olle Sangfelts forskargrupp
Artiklar
- Article: GENOME BIOLOGY. 2024;25(1):143Malyukova A; Lahnalampi M; Falques-Costa T; Poeloenen P; Sipola M; Mehtonen J; Teppo S; Akopyan K; Viiliainen J; Lohi O; Hagstroem-Andersson AK; Heinaeniemi M; Sangfelt O
- Article: MOLECULAR CELL. 2023;83(20):3720-3739.e8Brunner A; Li Q; Fisicaro S; Kourtesakis A; Viiliainen J; Johansson HJ; Pandey V; Mayank AK; Lehtio J; Wohlschlegel JA; Spruck C; Rantala JK; Orre LM; Sangfelt O
- Article: CANCER RESEARCH. 2022;82(24):4586-4603Borgenvik A; Holmberg KO; Bolin S; Zhao M; Savov V; Rosen G; Hutter S; Garancher A; Rahmanto AS; Bergstrom T; Olsen TK; Mainwaring OJ; Sattanino D; Verbaan AD; Rusert JM; Sundstrom A; Bravo MB; Dang Y; Wenz AS; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Giraud G; Chen X; Taylor MD; Sangfelt O; Clifford SC; Schueller U; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
- Journal article: NEURO-ONCOLOGY. 2021;23(Supplement_6):vi220-vi221Borgenvik A; Bolin S; Savov V; Holmberg KO; Zhao M; Rosén G; Hutter S; Garancher A; Rahmanto AS; Bergström T; Mainwaring O; Sattanino D; Verbaan AD; Rusert J; Sundström A; Dang Y; Wenz A; Richardson S; Fotaki G; Giraud G; Hill R; Dubuc A; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Chen X; Taylor MD; Sangfelt O; Clifford S; Schüller U; Wechsler-Reya R; Weishaupt H; Swartling F
- Article: SCIENTIFIC REPORTS. 2021;11(1):11023Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jonsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grander D; Brage SE; Johnsson P
- Article: ONCOTARGET. 2021;12(11):1100-1109Mäkelä R; Härmä V; Badra Fajardo N; Wells G; Lygerou Z; Sangfelt O; Kononen J; Rantala JK
- Article: ONCOGENE. 2021;40(13):2367-2381Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM
- Article: CELL. 2021;184(2):352-369.e23Shen JZ; Qiu Z; Wu Q; Finlay D; Garcia G; Sun D; Rantala J; Barshop W; Hope JL; Gimple RC; Sangfelt O; Bradley LM; Wohlschlegel J; Rich JN; Spruck C
- Article: SCIENTIFIC REPORTS. 2020;10(1):22334Richard TJC; Herzog LK; Vornberger J; Rahmanto AS; Sangfelt O; Salomons FA; Dantuma NP
- Journal article: NEURO-ONCOLOGY. 2020;22(Supplement_3):iii400Bolin S; Savov V; Borgenvik A; Rosén G; Olausson KH; Zhao M; Garancher A; Rahmanto AS; Hutter S; Mainwaring O; Rusert J; Sundstrom A; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Čančer M; Jernberg-Wiklund H; Ramaswamy V; Chen X; Taylor MD; Sangfelt O; Schüller U; Clifford SC; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
- Article: GENOME MEDICINE. 2020;12(1):99Mehtonen J; Teppo S; Lahnalampi M; Kokko A; Kaukonen R; Oksa L; Bouvy-Liivrand M; Malyukova A; Makinen A; Laukkanen S; Makinen PI; Rounioja S; Ruusuvuori P; Sangfelt O; Lund R; Lonnberg T; Lohi O; Heinaniemi M
- Article: NEOPLASIA. 2020;22(9):390-398Makela R; Arjonen A; Rahmanto AS; Harma V; Lehtio J; Kuopio T; Helleday T; Sangfelt O; Kononen J; Rantala JK
- Article: ELIFE. 2020;9:e57894Brunner A; Rahmanto AS; Johansson H; Franco M; Viiliainen J; Gazi M; Frings O; Fredlund E; Spruck C; Lehtio J; Rantala JK; Larsson L-G; Sangfelt O
- Journal article: NEURO-ONCOLOGY. 2019;21(Supplement_2):ii108-ii109Bolin S; Savov V; Borgenvik A; Rosen G; Garancher A; Rahmanto AS; Hutter S; Mainwaring O; Olausson KH; Rusert J; Sundstrom A; Richardson S; Fotaki G; Hill R; Dubuc A; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Ramaswamy V; Taylor M; Sangfelt O; Clifford S; Schuller U; Wechsler-Reya R; Weishaupt H; Swartling F
- Journal article: NEURO-ONCOLOGY. 2018;20(suppl_6):vi276Bolin S; Savov V; Borgenvik A; Garancher A; Rosén G; Rahmanto A; Hutter S; Rusert J; Garzia L; Fotaki G; Hill RM; Dubuc AM; Remke M; aner M; Ramaswamy V; Clifford S; Sangfelt O; Schüller U; Taylor M; Wechsler-Reya R; Weishaupt H; Swartling F
- Journal article: NEURO-ONCOLOGY. 2017;19(suppl_6):vi260-vi261Bolin S; Savov V; Borgenvik A; Garancher A; Rosén G; Rahmanto AS; Hutter S; Rusert J; Fotaki G; Hill R; Dubuc A; Remke M; Čančer M; Ramaswamy V; Clifford S; Sangfelt O; Schüller U; Taylor M; Wechsler-Reya R; Weishaupt H; Swartling F
- Article: MOLECULAR & CELLULAR ONCOLOGY. 2017;4(1):e1252871Rahmanto AS; Swartling FJ; Sangfelt O
- Article: EMBO JOURNAL. 2016;35(20):2192-2212Rahmanto AS; Savov V; Brunner A; Bolin S; Weishaupt H; Malyukova A; Rosen G; Cancer M; Hutter S; Sundstrom A; Kawauchi D; Jones DTW; Spruck C; Taylor MD; Cho Y-J; Pfister SM; Kool M; Korshunov A; Swartling FJ; Sangfelt O
- Article: FASEB JOURNAL. 2016;30(8):2860-2873Almuzzaini B; Sarshad AA; Rahmanto AS; Hansson ML; Von Euler A; Sangfelt O; Visa N; Farrants A-KO; Percipalle P
- Article: EMBO MOLECULAR MEDICINE. 2013;5(7):1067-1086Cepeda D; Ng H-F; Sharifi HR; Mahmoudi S; Soto Cerrato V; Fredlund E; Magnusson K; Nilsson H; Malyukova A; Rantala J; Klevebring D; Vinals F; Bhaskaran N; Zakaria SM; Rahmanto AS; Grotegut S; Nielsen ML; Szigyarto CA-K; Sun D; Lerner M; Navani S; Widschwendter M; Uhlen M; Jirstrom K; Ponten F; Wohlschlegel J; Grander D; Spruck C; Larsson L-G; Sangfelt O
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2013;162(2):210-220Gatt ME; Takada K; Mani M; Lerner M; Pick M; Hideshima T; Carrasco DE; Protopopov A; Ivanova E; Sangfelt O; Grander D; Barlogie B; Shaughnessy JDJ; Anderson KC; Carrasco DR
- Article: LEUKEMIA. 2013;27(5):1053-1062Malyukova A; Brown S; Papa R; O'Brien R; Giles J; Trahair TN; Dalla Pozza L; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Sangfelt O; Marshall GM
- Article: MOLECULAR AND CELLULAR BIOLOGY. 2013;33(1):85-97Bhaskaran N; van Drogen F; Ng H-F; Kumar R; Ekholm-Reed S; Peter M; Sangfelt O; Reed SI
- Article: NATURE COMMUNICATIONS. 2012;3:976Arabi A; Ullah K; Branca RMM; Johansson J; Bandarra D; Haneklaus M; Fu J; Aries I; Nilsson P; Den Boer ML; Pokrovskaja K; Grander D; Xiao G; Rocha S; Lehtio J; Sangfelt O
- Article: CELL CYCLE. 2011;10(13):2172-2183Lerner M; Lundgren J; Akhoondi S; Jahn A; Ng H-F; Moqadam FA; Vrielink JAFO; Agami R; Den Boer ML; Grander D; Sangfelt O
- Article: BREAST CANCER RESEARCH. 2010;12(6):R105Akhoondi S; Lindstrom L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grander D; Sangfelt O
- Journal article: CANCER RESEARCH. 2009;69(23_Supplement):c21Grotegut S; Rogers J; Sangfelt O; Spruck CH
- Journal article: BLOOD. 2009;114(22):1786Gatt ME; Mani M; Lerner M; Hideshima T; Zhang Y; Dutta J; Carrasco DE; Protopopov A; Sangfelt O; Grander D; Barlogie B; Shaughnessy JD; Anderson KC; Carrasco DR
- Article: SCIENCE. 2009;326(5953):718-721Vashisht AA; Zumbrennen KB; Huang X; Powers DN; Durazo A; Sun D; Bhaskaran N; Persson A; Uhlen M; Sangfelt O; Spruck C; Leibold EA; Wohlschlegel JA
- Article: EXPERIMENTAL CELL RESEARCH. 2009;315(17):2941-2952Lerner M; Harada M; Loven J; Castro J; Davis Z; Oscier D; Henriksson M; Sangfelt O; Grander D; Corcoran MM
- Article: EXPERIMENTAL CELL RESEARCH. 2009;315(11):1832-1839Klotz K; Cepeda D; Tan Y; Sun D; Sangfelt O; Spruck C
- Article: CANCER CELL. 2009;15(5):441-453Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
- Article: CELL CYCLE. 2008;7(8):1075-1082Sangfelt O; Cepeda D; Malyukova A; van Drogen F; Reed SI
- Article: CANCER RESEARCH. 2007;67(19):9006-9012Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dofou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
- Article: EXPERIMENTAL CELL RESEARCH. 2007;313(14):3141-3152Dohda T; Maljukova A; Liu L; Heyman M; Grander D; Brodin D; Sangfelt O; Lendahl U
- Article: CANCER RESEARCH. 2007;67(12):5611-5616Malyukova A; Dohda T; von der Lehr N; Akhondi S; Corcoran M; Heyman M; Spruck C; Grander D; Lendahl U; Sangfelt O
- Article: MOLECULAR BIOLOGY OF THE CELL. 2007;18(5):1670-1682Lerner M; Corcoran M; Cepeda D; Nielsen ML; Zubarev R; Ponten F; Uhlen M; Hober S; Grander D; Sangfelt O
- Article: MOLECULAR CELL. 2006;23(1):37-48van Drogen F; Sangfelt O; Malyukova A; Matskova L; Yeh E; Means AR; Reed SI
- Article: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 2005;25(2):63-72Thyrell L; Sangfelt O; Zhivotovsky B; Pokrovskaja K; Wang YS; Einhorn S; Grandér D
- Article: HUMAN MOLECULAR GENETICS. 2004;13(23):2925-2936Hammarsund M; Lerner M; Zhu CY; Merup M; Jansson M; Gahrton G; Kluin-Nelemans H; Einhorn S; Grandér D; Sangfelt O; Corcoran M
- Article: GENES CHROMOSOMES & CANCER. 2004;40(4):285-297Corcoran MM; Hammarsund M; Zhu CY; Lerner M; Kapanadze B; Wilson B; Larsson C; Forsberg L; Ibbotson RE; Stefan E; Oscier DG; Grandér D; Sangfelt O
- Article: CANCER RESEARCH. 2004;64(3):795-800Reed SE; Spruck CH; Sangfelt O; van Drogen F; Mueller-Holzner E; Widschwendter M; Zetterberg A; Reed SI
- Article: FEBS LETTERS. 2004;556(1-3):75-80Hammarsund M; Corcoran MM; Wilson W; Zhu CY; Einhorn S; Sangfelt O; Grander D
- Article: GENE. 2003;321:103-112Baranova A; Hammarsund M; Ivanova DV; Skoblov M; Sangfelt O; Corcoran M; Borodina T; Makeeva N; Pestova A; Tyazhelova T; Nazarenko S; Gorreta F; Alsheddi T; Schlauch K; Nikitin E; Kapanadze B; Shagin D; Poltaraus A; Vorobiev AI; Zabarovsky E; Lukianov S; Chandhoke V; Ibbotson R; Oscier D; Einhorn S; Grander D; Yankovsky N
- Article: CANCER RESEARCH. 2002;62(16):4535-4539Spruck CH; Strohmaier H; Sangfelt O; Müller HM; Hubalek M; Müller-Holzner E; Marth C; Widschwendter M; Reed SI
- Article: ONCOGENE. 2002;21(8):1251-1262Thyrell L; Erickson S; Zhivotovsky B; Pokrovskaja K; Sangfelt O; Castro J; Einhorn S; Grandér D
- Article: FEBS JOURNAL. 2002;269(1):29-37Erickson S; Matikainen S; Thyrell L; Sangfelt O; Julkunen I; Einhorn S; Grandér D
- Article: RUSSIAN JOURNAL OF GENETICS. 2001;37(11):1286-1292Tyazhelova TV; Ivanov DV; Makeeva NV; Kapanadze BI; Nikitin EA; Semov AB; Sangfelt O; Grander D; Vorobiev AI; Einhorn S; Yankovsky NK; Baranova AV
- Article: HUMAN GENETICS. 2001;109(5):542-550Hammarsund M; Wilson W; Corcoran M; Merup M; Einhorn S; Grandér D; Sangfelt O
- Article: NATURE. 2001;413(6853):316-322Strohmaier H; Spruck CH; Kaiser P; Won KA; Sangfelt O; Reed SI
- Journal article: BLOOD. 2000;96(13):4313-4318Xu D; Erickson S; Szeps M; Gruber A; Sangfelt O; Einhorn S; Pisa P; Grandér D
- Article: GENOMICS. 2000;70(3):327-334Kapanadze B; Makeeva N; Corcoran M; Jareborg N; Hammarsund M; Baranova A; Zabarovsky E; Vorontsova O; Merup M; Gahrton G; Jansson M; Yankovsky N; Einhorn S; Oscier D; Grandér D; Sangfelt O
- Article: BLOOD. 2000;96(13):4313-4318Xu DW; Erickson S; Szeps M; Gruber A; Sangfelt O; Einhorn S; Pisa P; Grandér D
- Article: MOLECULAR CANCER RESEARCH. 1999;10(8):575-582Erickson S; Sangfelt O; Castro J; Heyman M; Einhorn S; Grandér D
- Article: ONCOGENE. 1999;18(18):2798-2810Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
- Article: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 1998;18(9):691-695Grandér D; Sangfelt O; Skoog L; Hansson J
- Article: ONCOGENE. 1998;17(5):595-602Erickson S; Sangfelt O; Heyman M; Castro J; Einhorn S; Grandér D
- Article: MOLECULAR CANCER RESEARCH. 1997;8(3):343-352Sangfelt O; Erickson S; Castro J; Heiden T; Einhorn S; Grander D
- Article: ONCOGENE. 1997;14(4):415-423Sangfelt O; Erickson S; Einhorn S; Grander D
- Article: INTERNATIONAL JOURNAL OF CANCER. 1996;67(1):106-112Sangfelt O; Einhorn S; Bjorklund AC; Wiman KG; Okan I; Grander D
- Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 1996;31(6):604-611Grander D; Hultcrantz R; Weiland O; Xu B; Sangfelt O; Bjorklund AC; Befrits R; Bjorkholm M; Gruber A; Kinnman N; Reichard O; Widell A; Einhorn S
- Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(2):190-192SANGFELT O; OSTERBORG A; GRANDER D; ANDERBRING E; OST A; MELLSTEDT H; EINHORN S
- Journal article: BLOOD. 1994;84(6):1942-1949XU B; GRANDER D; SANGFELT O; EINHORN S
- Visa fler
Alla övriga publikationer
- Preprint: BIORXIV. 2023Malyukova A; Lahnalampi M; Falqués-Costa T; Pölönen P; Sipola M; Mehtonen J; Teppo S; Viiliainen J; Lohi O; Hagström-Andersson AK; Heinäniemi M; Sangfelt O
- Conference publication: BLOOD. 2022;140:11576Malyukova A; Lahnalampi M; Falques T; Polonen P; Sipola M; Mehtonen J; Teppo S; Viiliainen J; Lohi O; Hagstroem-Andersson A; Heinaniemi M; Sangfelt O
- Conference publication: NEURO-ONCOLOGY. 2021;23:220-221Borgenvik A; Bolin S; Savov V; Holmberg KO; Zhao M; Rosen G; Hutter S; Garancher A; Rahmanto AS; Bergstrom T; Mainwaring O; Sattanino D; Verbaan AD; Rusert J; Sundstrom A; Dang Y; Wenz A; Richardson S; Fotaki G; Giraud G; Hill R; Dubuc A; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Chen X; Taylor MD; Sangfelt O; Clifford S; Schuller U; Wechsler-Reya R; Weishaupt H; Swartling F
- Conference publication: NEURO-ONCOLOGY. 2020;22:400Bolin S; Savov V; Borgenvik A; Rosen G; Olausson KH; Zhao M; Garancher A; Rahmanto AS; Hutter S; Mainwaring O; Rusert J; Sundstrom A; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Ramaswamy V; Chen X; Taylor MD; Sangfelt O; Schueller U; Clifford SC; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
- Conference publication: CANCER RESEARCH. 2020;80(16):2371Brunner A; Johansson H; Kourtesakis A; Rantala J; Spruck C; Wohlschlegel J; Lehtio J; Sangfelt O
- Preprint: BIORXIV. 2020Mehtonen J; Teppo S; Lahnalampi M; Kokko A; Kaukonen R; Oksa L; Bouvy-Liivrand M; Malyukova A; Laukkanen S; Mäkinen PI; Rounioja S; Ruusuvuori P; Sangfelt O; Lund R; Lönnberg T; Lohi O; Heinäniemi M
- Preprint: BIORXIV. 2020Vidarsdottir L; Azimi A; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grandér D; Brage SE; Johnsson P
- Conference publication: NEURO-ONCOLOGY. 2019;21:108-109Bolin S; Savov V; Borgenvik A; Rosen G; Garancher A; Rahmanto AS; Hutter S; Mainwaring O; Olausson KH; Rusert J; Sundstrom A; Richardson S; Fotaki G; Hill R; Dubuc A; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Ramaswamy V; Taylor M; Sangfelt O; Clifford S; Schuller U; Wechsler-Reya R; Weishaupt H; Swartling F
- Conference publication: NEURO-ONCOLOGY. 2018;20:276Bolin S; Savov V; Borgenvik A; Garancher A; Rosen G; Rahmanto A; Hutter S; Rusert J; Garzia L; Fotaki G; Hill RM; Dubuc AM; Remke M; Aner M; Ramaswamy V; Clifford S; Sangfelt O; Schueller U; Taylor M; Wechsler-Reya R; Weishaupt H; Swartling F
- Conference publication: NEURO-ONCOLOGY. 2017;19:260-261Bolin S; Savov V; Borgenvik A; Garancher A; Rosen G; Rahmanto AS; Hutter S; Rusert J; Fotaki G; Hill R; Dubuc A; Remke M; Cancer M; Ramaswamy V; Clifford S; Sangfelt O; Schueller U; Taylor M; Wechsler-Reya R; Weishaupt H; Swartling F
- Corrigendum: CANCER CELL. 2017;31(5):724-726Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
- Review: ONCOGENE. 2014;33(39):4709-4721Hede S-M; Savov V; Weishaupt H; Sangfelt O; Swartling FJ
- Conference publication: BLOOD. 2009;114(22):710Gatt ME; Mani M; Lerner M; Hideshima T; Zhang Y; Dutta J; Carrasco DE; Protopopov A; Sangfelt O; Grander D; Barlogie B; Shaughnessy JDJ; Anderson KC; Carrasco DR
- Review: CANCER LETTERS. 2008;271(1):1-12Tan Y; Sangfelt O; Spruck C
- Corrigendum: CANCER RESEARCH. 2008;68(6):2051Malyukova A; Dohda T; von der Lehr N; Akhoondi S; Corcoran M; Heyman M; Spruck C; Grander D; Lendahl U; Sangfelt O
- Corrigendum: CANCER RESEARCH. 2008;68(4):1245Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Capeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
- Book chapter: HORMONAL CARCINOGENESIS IV. 2005;p. 98-105Spruck CH; Smith APL; Reed SE; Sangfelt O; Keck J; Strohmaier H; Méndez J; Widschwendter M; Stillman B; Zetterberg A; Reed SI
- Meeting abstract: BLOOD. 2004;104(11):431ACorcoran MM; Hammarsund M; Zhu CY; Lerner M; Kapanadze B; Larsson C; Forsberg L; Ibbotson RE; Einhorn S; Oscier DG; Grander D; Sangfelt O
- Meeting abstract: BLOOD. 2004;104(11):430ALerner M; Hammarsund M; Sangfelt O; Zhu CY; Merup M; Jansson M; Gahrton G; Kluin-Nelemans H; Einhorn S; Grander D; Corcoran M
- Review: MEDICAL ONCOLOGY. 2001;18(1):3-14Sangfelt O; Strander H
- Conference publication: BLOOD. 2000;96(11):703AKapanadze B; Makeevaa N; Corcoran MM; Jareborg N; Hammarsund M; Baranova A; Zabarovsky E; Vorontcova O; Merup M; Jansson O; Gahrton G; Oscier DG; Einhorn S; Grander D; Sangfelt O
- Conference publication: BLOOD. 2000;96(11):702A-703ACorcoran MM; Sangfelt O; Kapanadze B; Makeevaa N; Ibbotson RE; Baranova A; Zabarovsky E; Merup M; Jansson O; Gahrton G; Einhorn S; Grander D; Oscier DG
- Review: FRONTIERS IN BIOSCIENCE - LANDMARK. 2000;5:D479-D487Sangfelt O; Erickson S; Grandér D
- Conference publication: BLOOD. 1999;94(10):148BGrandér D; Erickson S; Matikainen S; Sangfelt O; Julkunen I; Einhorn S
- Review: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;59(3):129-135Grander D; Sangfelt O; Erickson S
- Conference publication: EUROPEAN JOURNAL OF CELL BIOLOGY. 1997;72:69Erickson S; Sangfelt O; Heyman M; Castro J; Einhorn S; Grander D
- Visa fler
Forskningsbidrag
- Swedish Research Council1 January 2024 - 31 December 2026Despite significant progress in cancer treatment, a considerable number of patients continue to experience relapse or inadequate responses, even when undergoing aggressive multimodal therapies. A major obstacle in devising effective therapeutic strategies lies in the difficulty of targeting key proteins that drive cancer metastasis and immune evasion, thereby contributing to the development of drug resistance. This underscores the importance of developing therapies that target these aspects of cancer biology to improve treatment outcomes. The purpose of this collaborative project between Dr. Guardavaccaro at the University of Verona and Dr. Sangfelt at Karolinska Institutet is to utilize ubiquitin ligases as an innovative strategy to prevent cancer metastasis and combat immune evasion. To execute this project, we have assembled a focused consortium of scientists who possess diverse expertise in SCF ubiquitin ligases, DNA replication stress and repair, cell motility and invasion, drug screening and medical chemistry. This consortium, which includes early-career researchers as well as tenured scientists, has been meticulously assembled to ensure the successful implementation of each research work package within the stipulated three-year timeframe. We will employ a unique combination of methodologies, merging an in vitro high-throughput nanoBRET-Ubiquitin screen with an in vivo functional compound screen in Zebrafish. This approach is designed to identify innovative compounds capable of disrupting the signaling of two clinically significant ubiquitin ligase-substrate pairs, FBXL12-FANCD2 and betaTrCP-SHARP1. The outcomes of this proof-of-concept project may unveil novel therapeutic strategies for combating cancer immune evasion and impeding the spread and metastatic growth, especially in aggressive basal-like breast cancer.
- Barncancerfonden1 January 2022 - 31 December 2022
- Swedish Research Council1 January 2021 - 31 December 2023
- Analyzes of enzymes that control vital signaling pathways in cancer cells and targeted therapy against these support systems in cancer tumors.Swedish Cancer Society1 January 2018Protein degradation (proteolysis) is a central biological mechanism that regulates basal functions of the cell such as cell division, cell death and gene activity. The degradation itself is performed by the so-called ubiquitin proteasome system and the discovery of this process was awarded in 2004 with the Nobel Prize. Proteins to be destroyed are first labeled with a small label, a protein called ubiquitin (Ub), and then rapidly broken down into the cellular debris, proteasomes. The degradation process is regulated by three enzyme activitiesE1, E2 and E3, where the so-called E3 ubiquitin enzymes determine which proteins to be broken down in the cell. We are studying an E3 enzyme in cancer cells. These have been shown to control a variety of cancer proteins that have been shown to be vital for cancer cell survival. The E3 enzyme Fbw7 is a protein that normally prevents cancer development and we have found that Fbw7 is often damaged in the cancer cells and that makes the cancer cells extra sensitive to certain cancer drugs. We have also discovered new E3 enzymes that play a very important role in the development and spread of cancer. In continuing studies, we will examine how these E3 enzymes affect the sensitivity of the cancer cells to various types of cancer drugs. The hope is that the results of our studies can be used in risk assessment and treatment strategy, but also lead in principle to new forms of cancer diagnosis and therapy. Several E3 enzymes have also been shown to be particularly attractive as molecular targets and we believe that the increased knowledge of how these enzymes control protein degradation will lead to increasingly individualized cancer treatments developing in the future.
- Analyzes of enzymes that control vital signaling pathways in cancer cells and targeted therapy against these support systems in cancer tumors.Swedish Cancer Society1 January 2017Protein degradation (proteolysis) is a central biological mechanism that regulates basal functions of the cell such as cell division, cell death and gene activity. The degradation itself is performed by the so-called ubiquitin proteasome system and the discovery of this process was awarded in 2004 with the Nobel Prize. Proteins to be destroyed are first labeled with a small label, a protein called ubiquitin (Ub), and then rapidly broken down into the cellular debris, proteasomes. The degradation process is regulated by three enzyme activitiesE1, E2 and E3, where the so-called E3 ubiquitin enzymes determine which proteins to be broken down in the cell. We are studying an E3 enzyme in cancer cells. These have been shown to control a variety of cancer proteins that have been shown to be vital for cancer cell survival. The E3 enzyme Fbw7 is a protein that normally prevents cancer development and we have found that Fbw7 is often damaged in the cancer cells and that makes the cancer cells extra sensitive to certain cancer drugs. We have also discovered new E3 enzymes that play a very important role in the development and spread of cancer. In continuing studies, we will examine how these E3 enzymes affect the sensitivity of the cancer cells to various types of cancer drugs. The hope is that the results of our studies can be used in risk assessment and treatment strategy, but also lead in principle to new forms of cancer diagnosis and therapy. Several E3 enzymes have also been shown to be particularly attractive as molecular targets and we believe that the increased knowledge of how these enzymes control protein degradation will lead to increasingly individualized cancer treatments developing in the future.
- Analyzes of enzymes that control the degradation of important cancer proteins.Swedish Cancer Society1 January 2016A very important biological mechanism that regulates cell division, cell death and gene expression is the degradation of proteins (proteolysis). The degradation itself is performed by the so-called ubiquitin proteasome system and the discovery of this process was awarded in 2004 with the Nobel Prize. Proteins to be destroyed are labeled with a small label, a protein called ubiquitin (Ub). Proteins labeled with Ub are then rapidly degraded into the cellular debris, proteasomes. The degradation process is mainly regulated by three enzyme activitiesE1, E2 and E3, where the so-called E3 ubiquitin ligases determine which proteins in the cell to degrade. We study a certain family of E3 ligases, so-called SCF ligases. We have previously identified an E3 ligase, SCFFbw7, which controls the breakdown of several important cancer proteins. Fbw7 is a protein that normally prevents cancer development and we have found that Fbw7 is often damaged in cancer cells. We have also discovered new SCF ligases that play a very important role in the development and spread of cancer. In continuing studies, we will investigate whether these SCF ligases affect the cancer cells' sensitivity to various types of cancer drugs. It is hoped that the results of these studies can be used in risk assessment and treatment strategy, but also lead in principle to new forms of cancer diagnosis and therapy. Several SCF E3 ligases have proven to be particularly attractive as molecular target targets and we believe that the increased knowledge of how these enzymes control protein degradation will lead to increasingly individualized cancer treatments developing in the future.
- Analyzes of enzymes that control the degradation of important cancer proteins.Swedish Cancer Society1 January 2015A very important biological mechanism that regulates cell division, cell death and gene expression is the degradation of proteins (proteolysis). The degradation itself is performed by the so-called ubiquitin proteasome system and the discovery of this process was awarded in 2004 with the Nobel Prize. Proteins to be destroyed are labeled with a small label, a protein called ubiquitin (Ub). Proteins labeled with Ub are then rapidly degraded into the cellular debris, proteasomes. The degradation process is mainly regulated by three enzyme activitiesE1, E2 and E3, where the so-called E3 ubiquitin ligases determine which proteins in the cell to degrade. We study a certain family of E3 ligases, so-called SCF ligases. We have previously identified an E3 ligase, SCFFbw7, which controls the breakdown of several important cancer proteins. Fbw7 is a protein that normally prevents cancer development and we have found that Fbw7 is often damaged in cancer cells. We have also discovered new SCF ligases that play a very important role in the development and spread of cancer. In continuing studies, we will investigate whether these SCF ligases affect the cancer cells' sensitivity to various types of cancer drugs. It is hoped that the results of these studies can be used in risk assessment and treatment strategy, but also lead in principle to new forms of cancer diagnosis and therapy. Several SCF E3 ligases have proven to be particularly attractive as molecular target targets and we believe that the increased knowledge of how these enzymes control protein degradation will lead to increasingly individualized cancer treatments developing in the future.
- Swedish Research Council1 January 2015 - 31 December 2018
- Analyzes of enzymes that control the degradation of important cancer proteins.Swedish Cancer Society1 January 2014A very important biological mechanism that regulates cell division, cell death and gene expression is the degradation of proteins (proteolysis). The degradation itself is performed by the so-called ubiquitin proteasome system and the discovery of this process was awarded in 2004 with the Nobel Prize. Proteins to be destroyed are labeled with a small label, a protein called ubiquitin (Ub). Proteins labeled with Ub are then rapidly degraded into the cellular debris, proteasomes. The degradation process is mainly regulated by three enzyme activitiesE1, E2 and E3, where the so-called E3 ubiquitin ligases determine which proteins in the cell to degrade. We study a certain family of E3 ligases, so-called SCF ligases. We have previously identified an E3 ligase, SCFFbw7, which controls the breakdown of several important cancer proteins. Fbw7 is a protein that normally prevents cancer development and we have found that Fbw7 is often damaged in cancer cells. We have also discovered new SCF ligases that play a very important role in the development and spread of cancer. In continuing studies, we will investigate whether these SCF ligases affect the cancer cells' sensitivity to various types of cancer drugs. It is hoped that the results of these studies can be used in risk assessment and treatment strategy, but also lead in principle to new forms of cancer diagnosis and therapy. Several SCF E3 ligases have proven to be particularly attractive as molecular target targets and we believe that the increased knowledge of how these enzymes control protein degradation will lead to increasingly individualized cancer treatments developing in the future.
- Swedish Research Council1 January 2012 - 31 December 2014
- Swedish Research Council1 January 2009 - 31 December 2011
- Swedish Research Council1 January 2009 - 31 October 2014
Anställningar
- Senior Forskare, Cell- och molekylärbiologi, Karolinska Institutet, 2022-
Examina och utbildning
- Docent, Cellbiologi, Karolinska Institutet, 2011
- MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 1998